Baxter Pays $150 Mil. For Somatogen Recombinant Hemoglobin Technology
Executive Summary
Baxter will pay about $150 mil. for a chance to apply Somatogen's recombinant hemoglobin technology to its blood substitute program.
You may also be interested in...
VitaResc Acquisition Of Apex To Fund Septic Shock Treatment Phase III Study
The acquisition of Apex Bioscience by Munich-based start-up VitaResc Biotech AG will provide for the financing of a Phase III program in nitric oxide-induced shock with Apex' lead product, pyridoxalated hemoglobin polyoxyethylene.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011